NDAINJECTIONINJECTABLE
Approved
Dec 2008
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NEXTERONE (amiodarone hydrochloride) by Baxter is drug, but it possesses electrophysiologic characteristics of all four vaughan williams classes. First approved in 2008.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXTERONE is an intravenous formulation of amiodarone hydrochloride, a broad-spectrum antiarrhythmic agent with electrophysiologic properties across all four Vaughan-Williams classes. It is used to treat life-threatening ventricular arrhythmias and hemodynamically unstable atrial fibrillation in acute care settings. The drug works by blocking sodium, potassium, and calcium channels while exerting noncompetitive antisympathetic effects, thereby slowing cardiac conduction and prolonging refractoriness.
Peak6.7 years to LOE
NEXTERONE is in peak commercial phase with no direct generic competitors, indicating stable revenue and moderate-sized brand team focused on hospital and acute-care channels.
Mechanism of Action
drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. One of its main effects, with…
Indications
Worked on NEXTERONE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.